已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Two-drug regimens with dolutegravir plus rilpivirine or lamivudine in HIV-1 treatment-naïve, virologically-suppressed patients: Latest evidence from the literature on their efficacy and safety

杜鲁特格拉维尔 利比韦林 医学 拉米夫定 临床试验 背景(考古学) 病毒学 肿瘤科 药理学 内科学 人类免疫缺陷病毒(HIV) 病毒载量 抗逆转录病毒疗法 病毒 乙型肝炎病毒 古生物学 生物
作者
Valeria Cento,Carlo Federico Perno
出处
期刊:Journal of global antimicrobial resistance [Elsevier]
卷期号:20: 228-237 被引量:27
标识
DOI:10.1016/j.jgar.2019.08.010
摘要

In the HIV-1-positive population, a paradigm shift from three-drug regimens (3DRs) to dolutegravir-based two-drug regimens (2DRs) both as initial and switch treatment is beginning to take place, supported virologically by the availability of new potent drugs with high genetic barrier to overcome, at least in certain conditions, the dogma of 3DRs in effective HIV-1 therapy. This manuscript reviews the increasing evidence on their excellent and sustained long-term effectiveness and safety. This review includes the most recent results on dolutegravir plus rilpivirine or lamivudine 2DRs from randomised clinical trials, meta-analyses and real-life studies, including relevant data presented at international conferences up to August 2019. As an initial treatment strategy, dolutegravir plus lamivudine showed high efficacy and safety over 96 weeks in 1441 patients from the GEMINI-1&2 phase III non-inferiority trials. In the SWORD 1&2 trials in virologically-suppressed patients, switching to once-daily dolutegravir plus rilpivirine maintained efficacy over 148 weeks. Similarly, in the TANGO trial, no confirmed virological withdrawals were observed with dolutegravir/lamivudine through Week 48. Consistent results were observed in real-life cohorts. No emergent dolutegravir-resistant virus has ever been reported in a patient in whom dolutegravir was prescribed in the context of such 2DRs. Switching to once-daily dolutegravir plus rilpivirine or lamivudine was generally well tolerated and was associated with favourable renal and bone safety. The results available so far support dolutegravir-based 2DRs as excellent treatment options for adults with HIV-1 infection, either naïve or already virologically suppressed on their current antiretroviral regimen.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
momo完成签到,获得积分10
1秒前
啾啾同学发布了新的文献求助10
3秒前
可爱的函函应助xixixi采纳,获得10
5秒前
9秒前
10秒前
星辰大海应助一两风采纳,获得10
11秒前
赵酬海完成签到 ,获得积分10
11秒前
Dr大壮完成签到,获得积分10
11秒前
领导范儿应助临床小白采纳,获得10
14秒前
爆米花应助临床小白采纳,获得10
14秒前
荼靡落时发布了新的文献求助10
16秒前
ling_lz完成签到,获得积分10
17秒前
无奈乐松应助fifteen采纳,获得10
17秒前
gui完成签到,获得积分10
18秒前
隐形曼青应助minisword采纳,获得10
20秒前
22秒前
小蚂蚁完成签到,获得积分10
23秒前
小二郎应助无zzz的人采纳,获得10
26秒前
29秒前
30秒前
Liu完成签到,获得积分10
30秒前
31秒前
一两风发布了新的文献求助10
34秒前
Liu发布了新的文献求助10
34秒前
梧桐完成签到,获得积分10
35秒前
共享精神应助sandra采纳,获得10
36秒前
安徒发布了新的文献求助10
36秒前
39秒前
bear应助科研通管家采纳,获得10
39秒前
39秒前
思源应助科研通管家采纳,获得10
39秒前
JamesPei应助科研通管家采纳,获得10
40秒前
今后应助科研通管家采纳,获得10
40秒前
bkagyin应助科研通管家采纳,获得10
40秒前
今后应助科研通管家采纳,获得10
40秒前
Ava应助科研通管家采纳,获得10
40秒前
蒋时晏应助科研通管家采纳,获得20
40秒前
小蘑菇应助科研通管家采纳,获得10
40秒前
情怀应助科研通管家采纳,获得10
40秒前
高分求助中
Evolution 2024
中国国际图书贸易总公司40周年纪念文集: 回忆录 2000
Impact of Mitophagy-Related Genes on the Diagnosis and Development of Esophageal Squamous Cell Carcinoma via Single-Cell RNA-seq Analysis and Machine Learning Algorithms 2000
Experimental investigation of the mechanics of explosive welding by means of a liquid analogue 1060
Die Elektra-Partitur von Richard Strauss : ein Lehrbuch für die Technik der dramatischen Komposition 1000
How to Create Beauty: De Lairesse on the Theory and Practice of Making Art 1000
Gerard de Lairesse : an artist between stage and studio 670
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3004344
求助须知:如何正确求助?哪些是违规求助? 2663653
关于积分的说明 7218821
捐赠科研通 2299988
什么是DOI,文献DOI怎么找? 1219803
科研通“疑难数据库(出版商)”最低求助积分说明 594479
版权声明 593117